SCHEMBL6936010

SCHEMBL6936010

CC(=O)N[C@@](C)(NC(=O)OC(C)(C)C)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.49
ALDH1A1 P00352 3/20 0.48
RECQL P46063 1/20 0.48
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
PPARA Q07869 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
IDO1 P14902 1/20 0.43
LMNA P02545 1/20 0.43
AKT1 P31749 2/20 0.42
CTSS P25774 1/20 0.41
MAPT P10636 1/20 0.41
CTSL P07711 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3414241 0.85 MEN1 (0.59) SYKALDH1A1MEN1KMT2ACA12
SCHEMBL1728479 0.83 SYK (0.53) SYKALDH1A1MEN1KMT2ACA12
SCHEMBL7216943 0.81 SYK (0.54) SYKALDH1A1MEN1KMT2ACA12
SCHEMBL27524219 0.80 SYK (0.50) SYKALDH1A1MEN1KMT2ACA12
SCHEMBL21239559 0.80 SYK (0.53) SYKALDH1A1RECQLMEN1KMT2A
SCHEMBL7432755 0.80 SYK (0.53) SYKALDH1A1RECQLMEN1KMT2A
SCHEMBL7434905 0.80 SYK (0.50) SYKALDH1A1RECQLMEN1KMT2A
SCHEMBL8312542 0.80 SYK (0.50) SYKALDH1A1MEN1KMT2ACA12
SCHEMBL29291807 0.80 SYK (0.53) SYKALDH1A1RECQLMEN1KMT2A
SCHEMBL19862502 0.79 SYK (0.49) SYKALDH1A1MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114488-A1 New processes for producing beta-alanine derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-19 US disclosed
US-6538007-B1 Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114488-A1 New processes for producing beta-alanine derivatives BCAT1, BCAT2, AGXT SYK 4836/4885ALDH1A1 572/4885RECQL 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.